重资产影像网络构筑"数据入口"，为AI与数据资产化提供稀缺底座 公司通过重资产投入建立了覆盖全国的影像中心网络，截至2025年6月30日已运营115家影像中心，覆盖 17个省份，并持有国内领先数量的第三方影像中心牌照，形成设备、牌照、医生资源和品牌等多重壁 垒。影像中心既是收入"压舱石"，也是高质量结构化影像数据的主要生产场景，为后续数据资产化、AI 训练和商业化落地提供稀缺底座。 数据资产化+全模态大模型，构建"数据-算法-应用"的医疗AI平台闭环 智通财经APP获悉，天风证券发布研报称，预计一脉阳光(02522)2025-2027年营业收入为10.5、13.9、 16.8亿元，同比+38.1%、+32.2%、+21.2%;净利润为0.25、0.60、1.05亿元，2026、2027年同比增速为 137.7%、76.5%;EBITDA为2.36、2.82、3.41亿元，同比+43.0%、+19.5%、+20.9%。考虑到公司作为中 国三方医学影像行业领导者的稀缺性以及作为医疗数据资产运营商的未来发展空间，该行给予公司2026 年8倍PS，对应市值111.1亿元，折合港币为121.9亿港元(2025年11月1 ...

Core Viewpoint - The company is expected to achieve steady growth in H1 2025, driven by its light-asset, modular imaging solution service model, which is anticipated to increase revenue and customer numbers [1][3] Financial Performance - In H1 2025, the company reported revenue of 467 million yuan, a year-on-year increase of 12.9%, and a net profit attributable to shareholders of 16.44 million yuan, a year-on-year increase of 328.6% [1][2] - The adjusted EBITDA after deducting non-recurring items was 135 million yuan, reflecting an 18.7% year-on-year growth [1] Business Segmentation - Imaging center service revenue was 300 million yuan, down 6.1% year-on-year, primarily due to macroeconomic fluctuations and stricter medical industry regulations [2] - Imaging solution revenue reached 161 million yuan, up 88.9% year-on-year, attributed to a significant increase in customer numbers [2] - OneCloud service revenue was 65 million yuan, down 31.9% year-on-year, mainly due to a decrease in one-time software sales [2] Strategic Initiatives - The company has implemented a "one certificate, multiple sites" model to facilitate efficient expansion through regional shared sub-centers [2] - In June, the company completed the acquisition of 70% of Gaomai Health, enhancing its capabilities in nuclear medicine [2] - As of June 30, 2025, the company had 11 imaging centers under construction, expected to begin operations in the second half of the year [2] Market Expansion - The company has successfully adopted a light-asset modular product strategy, lowering customer entry barriers and adding 354 new clients during the reporting period [3] - The company has signed 15 project contracts in overseas markets, marking significant progress in its international expansion [3] Data and AI Development - The company is advancing its data and AI initiatives, establishing a complete "data-algorithm-scenario" ecosystem [3] - The launch of the "CT chest lesion annotation data" product on the Shanghai Data Exchange signifies a transition of data from "resource" to "asset" [3] - Strategic partnerships with industry leaders like iFlytek Medical and Huawei Cloud are being formed to develop smart medical solutions [3] Outlook - The company anticipates continued revenue improvement in H2 2025, supported by the operation of new imaging centers and the light-asset model [3] - The OneCloud platform, along with policies for imaging result recognition and cloud indexing, is expected to enhance operational efficiency and synergy [3] Profitability and Cost Management - The gross margin for H1 2025 was 29.4%, a decrease of 9.2 percentage points year-on-year, due to increased competition and regulatory changes [4] - Effective cost control measures led to a reduction in sales expenses by 18.42% and administrative expenses by 32.50% [4][5] - The net cash flow from operating activities increased by 172.6% to 93.02 million yuan, attributed to improved management of receivables [5] Profit Forecast and Valuation - Short-term revenue growth is expected to be driven by the rapid expansion of light-asset imaging solutions and new imaging centers [5] - Long-term growth is anticipated through the synergistic effects of the company's three main business segments, supported by AI technology [5] - Revenue projections for 2025-2027 are 1.005 billion, 1.241 billion, and 1.494 billion yuan, with corresponding net profit estimates of 33 million, 79 million, and 122 million yuan [5]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][22][26] Core Viewpoints - The company achieved a revenue growth of 12.9% year-on-year in the first half of 2025, reaching 467 million yuan, and turned a profit with a net profit of 16 million yuan, compared to a loss in 2024 [1][8] - The growth in revenue is attributed to the rapid expansion of clients in imaging center services and imaging solution services, alongside optimized resource allocation and reduced unnecessary expenses [1][8] - The company is positioned as a leader in the domestic medical imaging service sector, with a steady expansion pace and a focus on AI-driven comprehensive imaging solutions [3][22] Revenue and Profitability - In the first half of 2025, imaging center service revenue was 300 million yuan, down 6.1% due to macroeconomic fluctuations and policy adjustments [2][10] - Imaging solution service revenue surged by 88.9% to approximately 161 million yuan, driven by the ongoing benefits of new medical infrastructure policies and the recovery of medical equipment upgrade demands [2][10] - The company's gross margin was 29.4%, a decrease of 9.2 percentage points, primarily due to adjustments in imaging examination fees [3][15] Financial Forecasts - The company forecasts net profits of 49 million yuan, 81 million yuan, and 113 million yuan for 2025, 2026, and 2027 respectively, reflecting a turnaround and growth rates of 65.3% and 39.5% [3][22] - Revenue projections for 2025, 2026, and 2027 are 997 million yuan, 1.227 billion yuan, and 1.477 billion yuan, indicating growth rates of 31.1%, 23.1%, and 20.3% respectively [4][24] Operational Developments - The company has developed 11 new imaging centers and commenced operations at 12 centers, with 11 more under construction, which are expected to contribute to revenue stability in the second half of 2025 [2][10] - The company launched a medical imaging large model computing machine in collaboration with Alibaba Cloud, enhancing its capabilities in AI medical imaging [2][10]

Financial Data and Key Metrics Changes - The company reported a significant increase in inpatient admissions year over year, leading the peer group in growth [20][21] - Adjusted EBITDAR margins improved to over 12% in Q2, a 200 basis point increase from the previous year [48][49] - The company expects to achieve mid-teens margins, comparable to peers, through ongoing margin improvement initiatives [48][49] Business Line Data and Key Metrics Changes - Inpatient surgeries increased by approximately 7% in Q2, indicating the effectiveness of the company's service line rationalization strategy [23][24] - The company is focusing on expanding outpatient services, including urgent care and ambulatory surgery centers, to enhance access points for patients [6][74] - The company has added 18 urgent care facilities this year, with a significant portion of patients being new to the system [27][72] Market Data and Key Metrics Changes - The company operates in eight markets across six states, primarily in the South Central region, with these markets growing at an average rate three times faster than the U.S. average [5][16] - The competitive landscape primarily consists of local and regional nonprofits, with limited competition from for-profit peers [16][17] Company Strategy and Development Direction - The company's growth strategy focuses on deepening its presence in existing markets and expanding outpatient services to create a comprehensive care ecosystem [6][7] - The differentiated joint venture model with nonprofit and academic partners is a key aspect of the company's strategy, enhancing service offerings and operational efficiency [9][10] - The company is exploring opportunities for hospital M&A, particularly in non-expansion states, to further its growth objectives [78][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for services, attributing strong inpatient volume growth to an aging and sicker population [33][34] - The company is proactively addressing potential reimbursement changes and is optimistic about maintaining growth despite anticipated challenges [67][69] - Management highlighted the importance of technology and innovation in improving operational efficiency and patient care [42][51] Other Important Information - The company is experiencing a stabilization in labor costs, with a focus on improving workplace culture to retain staff [39][40] - There has been a notable increase in denial rates, but efforts are being made to manage and reduce these levels [34][35] Q&A Session Summary Question: What are the highlights from the first half of the year? - The company reported robust volume growth, particularly in inpatient admissions, and a focus on efficiency improvements [20][21] Question: How does the company view the slower volume growth in adjusted admissions? - Management attributed the lower adjusted admissions to a focus on higher acuity inpatient cases and ongoing development of outpatient assets [25][26] Question: What is the company's strategy regarding outpatient services? - The company is prioritizing the expansion of urgent care and ambulatory surgery centers, viewing them as high-return investments [71][74] Question: How is the company addressing denial rates? - Management noted that while initial denials have increased, final denials are stabilizing, indicating effective management efforts [34][35] Question: What is the outlook for Medicaid supplemental payments? - The company anticipates a manageable impact from potential reductions in Medicaid payments, with confidence in continued growth [66][67]

Investment Rating - The report gives a "Strong Buy" rating for the company with a target price of HKD 27.4 [1][9][12] Core Viewpoints - The company is positioned as a leader in the third-party medical imaging service sector in China, with significant growth potential driven by AI integration and a robust business model [10][11] - The imaging center business serves as the cornerstone of the company's revenue and competitive advantage, accounting for over 60% of total revenue [2][11] - The company aims to achieve 30% of its revenue from overseas markets within five years, leveraging its imaging solutions business [2][11] Summary by Sections Company Overview - The company, established in 2014, operates the largest number of medical imaging centers in China, with 115 centers and 33 valid third-party imaging center licenses as of June 2025 [15][17] - The business is divided into three main segments: imaging center services, imaging solutions services, and Yimai Cloud services, forming a comprehensive ecosystem [17][52] Industry Analysis - The third-party medical imaging service market in China has significant growth potential, with a current penetration rate of only 1% compared to over 40% in the U.S. [8][43] - The market size for medical imaging services in China is projected to grow from CNY 270.9 billion in 2023 to CNY 661.5 billion by 2030, with a CAGR of 13.6% [32][34] Business Model and Competitive Advantage - The imaging center business is the company's main revenue source and a key competitive moat, with various types of centers catering to different market needs [55][56] - The company has a strong management team with extensive industry experience, supported by notable institutional investors [22][25] Financial Projections - Revenue is expected to grow from CNY 10.11 billion in 2025 to CNY 15.88 billion by 2027, with net profits projected to increase significantly during the same period [4][12] - The company anticipates a recovery in 2025 after a decline in 2024 due to macroeconomic factors and increased operational costs [18][20]

Industry Insights - The third-party medical imaging service industry in China has significant potential, with a current penetration rate of only 1% compared to over 40% in the US, indicating a vast market opportunity [3][4] - AI technology is empowering the medical imaging sector through various applications, including equipment, auxiliary diagnosis, treatment support, and data quality control, which can enhance efficiency and reduce costs [3][4] - The third-party imaging centers serve as both producers of imaging data and application scenarios for AI, allowing them to generate additional revenue through licensing AI algorithms and data services [3][4] Company Overview - The company has established a one-stop ecosystem through three main business segments: imaging center services, imaging solution services, and Yimai Cloud services, which support and transform each other [3][4] - The imaging center business is the cornerstone of the company's revenue, accounting for over 60% of total income, and serves as a critical competitive advantage due to high market entry barriers [4] - The imaging solution business is rapidly growing, with a significant increase in users and high profitability potential, aiming for 30% of revenue from overseas markets within five years [4][5] - Yimai Cloud is a key component of the company's digital strategy, leveraging one of the largest and fastest-growing medical imaging databases in China to enhance data value [5] - The company plans to achieve revenues of 1.01 billion, 1.29 billion, and 1.59 billion yuan in 2025, 2026, and 2027, respectively, with net profits projected to reach 39 million, 83 million, and 141 million yuan during the same period [5]

Group 1 - The company, Yipai Sunshine, announced a financing plan through the placement of new H shares, issuing 35,000,000 shares to raise approximately HKD 590 million, with a net amount of about HKD 560 million after expenses [1] - The placement price of the new H shares is HKD 16.76, representing a discount of approximately 12.5% compared to the previous trading day's closing price of HKD 19.16, and a discount of about 17.3% compared to the average closing price over the last five trading days [1] - The newly issued shares will account for approximately 9.6% of the existing issued share capital and approximately 8.8% of the enlarged share capital after completion [1] Group 2 - The funds raised will be allocated towards the development of data and artificial intelligence, expansion of medical imaging center operations, enabling solution services, and potential investments or establishment of an industrial incubation fund, as well as general working capital [1] - Yipai Sunshine operates as a specialized medical imaging group and imaging platform service provider, focusing on imaging center services, imaging solutions, and Yipai Cloud services [1]

Core Viewpoint - The company reported a significant increase in mid-term performance for the six months ending June 30, 2025, with revenue reaching 467 million RMB, a year-on-year increase of 12.89% [1] Financial Performance - Revenue for the reporting period was 467 million RMB, with a gross profit of 137 million RMB [1] - Shareholder profit attributable to the company was 16.44 million RMB, reflecting a substantial year-on-year increase of 328.65% [1] - Basic earnings per share were reported at 0.046 RMB [1] Business Strategy and Market Position - The increase in revenue was primarily driven by a rise in customer numbers, despite macroeconomic slowdowns and adjustments in the reform process [1] - The company maintained stable revenue growth in its core imaging center services, even amidst industry cyclical adjustments [1] - The company is actively adjusting its business pace and expanding its medical imaging center network through investments, mergers, and the incubation of industrial funds [1] Future Outlook - New imaging center projects are expected to gradually commence operations in the second half of 2025 [1] - The ongoing release of national medical infrastructure policies is anticipated to boost business revenue significantly, with a recovery in demand for medical equipment expected by the end of 2024 [1] - The company is developing more flexible and diverse products, which have led to a notable increase in customer numbers, injecting new vitality into revenue growth [1]

自願公告 收購高脈健康股權 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出，以通知本公司股東（「股東」）及本 公司的潛在投資者有關本集團的最新業務發展。 董事會欣然宣佈，於2025年6月22日，本公司全資附屬公司江西贛江新區一脈陽 光健康管理有限公司（「一脈陽光健康管理」）（作為買方）、廣東高尚健康科技集團 有限公司（「賣方I」）、廈門高尚醫學影像診斷中心有限公司（「賣方II」）及合肥高 尚醫學影像診斷中心有限公司（「賣方III」）（作為賣方，統稱為「賣方」）與廣州高 脈健康科技有限公司（「高脈健康」）訂立股權轉讓協議（「股權轉讓協議」），據此， 一脈陽光健康管理將分別向賣方I、賣方II及賣方III收購高脈健康的30.0%、20.0% 及20.0%股權（「收購事項」），總代價為人民幣54,000,000元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi R ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 收購眾雅診斷股權 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出，以通知本公司股東（「股東」）及本 公司的潛在投資者有關本集團的最新業務發展。 董事會欣然宣佈，於2025年6月9日（交易時段後），本公司擁有55.0%權益的附屬 公司湖南一脈陽光醫學影像診斷中心有限公司（「湖南一脈」）（作為買方）、長沙市 眾雅健康產業集團有限公司（作為賣方，「賣方」）與長沙眾雅醫學影像診斷有限公 司（「眾雅診斷」）訂立股權轉讓協議（「股權轉讓協議」），據此，湖南一脈將向賣方 收購眾雅診斷的100.0%股權（「收購事項」），總代價為人民幣29,500,000元。 於本公告日期，湖南 ...